North China Pharmaceutical Company.Ltd (SHA:600812)
China flag China · Delayed Price · Currency is CNY
5.58
+0.04 (0.72%)
Feb 3, 2026, 3:00 PM CST

SHA:600812 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Operating Revenue
9,7229,79810,07010,44910,30411,430
Other Revenue
71.7671.7650.3251.1980.262.02
9,7949,87010,12010,50010,38511,493
Revenue Growth (YoY)
0.91%-2.48%-3.62%1.11%-9.64%0.31%
Cost of Revenue
6,7556,7326,9077,0636,6917,405
Gross Profit
3,0393,1383,2133,4373,6944,087
Selling, General & Admin
1,9082,0102,2682,4242,7963,179
Research & Development
338.29336.15294.2215.17151.93135.69
Other Operating Expenses
94.2290.82104.23117.57123.33137.44
Operating Expenses
2,3962,4652,6772,8023,0943,489
Operating Income
642.82672.93536.44634.8600.11597.87
Interest Expense
-389.27-458.7-501.9-599.39-642.69-572.02
Interest & Investment Income
78.2971.4274.5284.17126.6266
Currency Exchange Gain (Loss)
17.5717.5711.4923.31-8.32-29.94
Other Non Operating Income (Expenses)
-8.02-5.15-11.35-748.96-13.91-15.35
EBT Excluding Unusual Items
341.4298.08109.2-606.0761.8246.55
Impairment of Goodwill
-3.34-3.34----
Gain (Loss) on Sale of Assets
0.630.310.760.213.41.07
Asset Writedown
19.03-1.26-0.05---
Legal Settlements
-0.5-0.5-0.49-0.78-1.14-1.64
Other Unusual Items
16.8616.5549.1241.5670.84140.7
Pretax Income
374.07309.83158.54-565.07134.91186.68
Income Tax Expense
94.0194.87109.15113.7199.5282.2
Earnings From Continuing Operations
280.06214.9749.39-678.7835.38104.48
Minority Interest in Earnings
-97.03-87.97-44.5-10.45-16.65-7.15
Net Income
183.03126.994.89-689.2318.7397.32
Net Income to Common
183.03126.994.89-689.2318.7397.32
Net Income Growth
130.57%2496.79%---80.76%-43.46%
Shares Outstanding (Basic)
1,7271,7161,6301,7151,7021,622
Shares Outstanding (Diluted)
1,7271,7161,6301,7151,7021,622
Shares Change (YoY)
7.99%5.27%-4.92%0.70%4.96%-0.12%
EPS (Basic)
0.110.070.00-0.400.010.06
EPS (Diluted)
0.110.070.00-0.400.010.06
EPS Growth
113.52%2366.67%---81.67%-43.40%
Free Cash Flow
150.27445.35401.23454.81502.75-254.68
Free Cash Flow Per Share
0.090.260.250.270.29-0.16
Dividend Per Share
0.0300.0300.010-0.0600.030
Dividend Growth
200.00%200.00%--100.00%-
Gross Margin
31.03%31.79%31.75%32.73%35.57%35.56%
Operating Margin
6.56%6.82%5.30%6.05%5.78%5.20%
Profit Margin
1.87%1.29%0.05%-6.56%0.18%0.85%
Free Cash Flow Margin
1.53%4.51%3.96%4.33%4.84%-2.22%
EBITDA
1,4681,4611,2751,3471,2241,218
EBITDA Margin
14.99%14.81%12.60%12.83%11.79%10.60%
D&A For EBITDA
825.65788.52739.01712624620.12
EBIT
642.82672.93536.44634.8600.11597.87
EBIT Margin
6.56%6.82%5.30%6.05%5.78%5.20%
Effective Tax Rate
25.13%30.62%68.85%-73.77%44.03%
Revenue as Reported
9,7949,87010,12010,50010,38511,493
Advertising Expenses
-119.86133.01127.89185.19203.55
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.